Literature DB >> 14972553

Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques.

Peter Balfe1, Sarah Shapiro, Mayla Hsu, Clarisa Buckner, Janet M Harouse, Cecilia Cheng-Mayer.   

Abstract

Four successive, rapid serial passages of the nonpathogenic, CCR5-tropic simian-human immunodeficiency virus SHIV(SF162) in rhesus macaques resulted in an increase in acute plasma viremia with each passage and the emergence of a pathogenic isolate SHIV(SF162P3) in one of the passage three transfer animals (macaque T353). To explore the mechanism(s) underlying increased virulence of SHIV(SF162) upon in vivo passage, the evolution of the HIV-1 envelope gene was characterized in plasma and PBMC samples obtained from animals before (week 1) and after (week 3) the time of virus transfer. We found no evidence in support of adaptive evolution of the HIV gp120 during rapid serial passage; however, the animals which later received passage virus had more diverse quasispecies. SHIV(SF162P3)-like gp120 sequences were first detected in macaque T353 at week 6, after seroconversion. These sequence changes increased in frequency and number at later time points. The first sequence change conferred neutralization escape but not an increase in viral infectivity that could account for the apparent increase in replicative capacity of the later passage viruses. Collectively, our data argue against any host-specific adaptation of the HIV-1 envelope gp120 as the basis for the generation of more aggressive SHIV variants during rapid serial transfers in seronegative macaques, and support the model of quasispecies diversity as a predictor of pathogenesis. Envelope sequence changes accumulate principally in response to immune pressure exerted by the host, generating viral variants that can persist in the presence of a strong host immune response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972553     DOI: 10.1016/j.virol.2003.09.022

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.

Authors:  Nagadenahalli B Siddappa; Girish Hemashettar; Yin Ling Wong; Samir Lakhashe; Robert A Rasmussen; Jennifer D Watkins; Francis J Novembre; François Villinger; James G Else; David C Montefiori; Ruth M Ruprecht
Journal:  J Med Primatol       Date:  2010-11-02       Impact factor: 0.667

2.  Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.

Authors:  Christopher Sundling; Sijy O'Dell; Iyadh Douagi; Mattias N Forsell; Andreas Mörner; Karin Loré; John R Mascola; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.

Authors:  Samir K Lakhashe; Vijayakumar Velu; Gaia Sciaranghella; Nagadenahalli B Siddappa; Janet M Dipasquale; Girish Hemashettar; John K Yoon; Robert A Rasmussen; Feng Yang; Sandra J Lee; David C Montefiori; Francis J Novembre; François Villinger; Rama Rao Amara; Maria Kahn; Shiu-Lok Hu; Sufen Li; Zhongxia Li; Fred R Frankel; Marjorie Robert-Guroff; Welkin E Johnson; Judy Lieberman; Ruth M Ruprecht
Journal:  Vaccine       Date:  2011-07-14       Impact factor: 3.641

4.  Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Stephanie J Buchl; Donna Palmer; David C Montefiori; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

5.  R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.

Authors:  Nagadenahalli B Siddappa; Jennifer D Watkins; Klemens J Wassermann; Ruijiang Song; Wendy Wang; Victor G Kramer; Samir Lakhashe; Michael Santosuosso; Mark C Poznansky; Francis J Novembre; François Villinger; James G Else; David C Montefiori; Robert A Rasmussen; Ruth M Ruprecht
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

6.  Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements.

Authors:  Jesse Thompson; Martha MacMillan; Karen Boegler; Charles Wood; John H Elder; Sue VandeWoude
Journal:  PLoS One       Date:  2011-08-26       Impact factor: 3.240

7.  Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection.

Authors:  Samir K Lakhashe; Wendy Wang; Nagadenahalli B Siddappa; Girish Hemashettar; Patricia Polacino; Shiu-Lok Hu; François Villinger; James G Else; Francis J Novembre; John K Yoon; Sandra J Lee; David C Montefiori; Ruth M Ruprecht; Robert A Rasmussen
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

8.  In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.

Authors:  David Davis; Wim Koornstra; Zahra Fagrouch; Ernst J Verschoor; Jonathan L Heeney; Willy M J M Bogers
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

9.  Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Guojun Yang; Stephanie J Buchl; Patrick W Hanley; Donna Palmer; David C Montefiori; Guido Ferrari; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.